Mapi Pharma
PrivateLast Round
Corporate Funding
Jun 15, 2020
Total Funding Raised
$50M
Company Overview
Mapi Pharma operates in Healthcare & Life Sciences and is based in Ness Ziona. Its latest recorded funding round was a Corporate Funding round in June 2020.
Mapi Pharma is a clinical-stage biopharmaceutical company that develops improved, extended-release versions of existing commercially successful drugs, with a lead product candidate for Multiple Sclerosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mapi Pharma Comparables
Compare Mapi Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| DelSiTech | 81% | |
| MedinCell S.A. | 79% | |
| InnoCore Pharmaceuticals | 79% |
For institutional investors. Book with your work email.
Mapi Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Jun 15, 2020 | ||||
| VC Round | Nov 5, 2018 | ||||
| Corporate Funding | Apr 10, 2018 | ||||
| VC Round | Aug 17, 2017 | ||||
| VC Round | Jan 31, 2016 | ||||
Series A | May 27, 2015 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Mapi Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| aMoon | VC Round |
| Shavit Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 21, 2026
Monthly visitors grew 296% MoM, from 398 to 1.6K.
- Jun 15, 2020
$20M round led by Viatris Inc.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 12, 2026
Mapi Pharma is developing Cariprazine Depot, a once-monthly subcutaneous long-acting injectable formulation of cariprazine using its proprietary depot technology, with development continuing in an ongoing Phase I/IIa study as of Aug '26 in Israel.
For institutional investors. Book with your work email.
Mapi Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Mapi Pharma's valuation, stock price, and market status.
Is Mapi Pharma a public or private company?
Mapi Pharma is a private company.
What is the current stock price of Mapi Pharma?
Mapi Pharma is a private company, so its shares have no public market price. Caplight tracks Mapi Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Mapi Pharma worth (valuation)?
Valuation information for Mapi Pharma is not publicly available.
Can I buy Mapi Pharma stock?
Mapi Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Mapi Pharma's last funding round?
Mapi Pharma's most recent funding round was Corporate Funding on June 15, 2020.
Who are the main investors in Mapi Pharma?
Key investors in Mapi Pharma include aMoon, Shavit Capital.
Will Mapi Pharma IPO soon?
No public IPO plans have been announced for Mapi Pharma.
How can I track Mapi Pharma secondary market activity?
Caplight tracks bids, offers, and trades in Mapi Pharma's shares on secondary markets.